MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy
- PMID: 22993312
MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy
Abstract
Renal cell carcinoma (RCC) is a potentially curable disease, especially if the tumor is limited to the kidneys and no systemic metastatic spread has occurred by the time of diagnosis. Despite the potential for successful surgical removal of the tumor-bearing organ in localized stages and the likelihood of treatment success, the complications and long-term morbidity and mortality of RCC are difficult to accurately predict. The currently used drugs were developed based on the understanding of the molecular details of pathogenesis at the time, which has improved over the past several decades. However, more efforts should be made to improve early diagnosis, the surveillance of patients who undergo resection and treatment for metastatic RCC. Recently, small non-coding RNAs (microRNAs) were found to play pivotal roles in the metastatic dissemination of tumor cells in different types of cancer. The aim of this review is to provide an overview of the role of microRNAs in the pathogenesis of RCC and to discuss their potential as diagnostic, prognostic and, ultimately, therapeutic biomolecules.
Similar articles
-
Renal cell carcinoma: current status and emerging therapies.Cancer Treat Rev. 2007 May;33(3):299-313. doi: 10.1016/j.ctrv.2006.12.005. Epub 2007 Feb 27. Cancer Treat Rev. 2007. PMID: 17329029 Review.
-
Gene expression profiling of renal cell carcinoma.Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6315S-21S. doi: 10.1158/1078-0432.CCR-050002. Clin Cancer Res. 2004. PMID: 15448024 Review.
-
Renal cell carcinoma: basic biology and clinical behavior.Semin Urol Oncol. 1996 Nov;14(4):208-15. Semin Urol Oncol. 1996. PMID: 8946619 Review.
-
[DNA and microRNA microarray technologies in diagnostics and prediction for patients with renal cell carcinoma].Klin Onkol. 2009;22(5):202-9. Klin Onkol. 2009. PMID: 19886357 Review. Czech.
-
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.J Urol. 2005 Jun;173(6):1853-62. doi: 10.1097/01.ju.0000165693.68449.c3. J Urol. 2005. PMID: 15879764 Review.
Cited by
-
MicroRNA-384 Inhibits the Growth and Invasion of Renal Cell Carcinoma Cells by Targeting Astrocyte Elevated Gene 1.Oncol Res. 2018 Apr 10;26(3):457-466. doi: 10.3727/096504017X15035025554553. Epub 2017 Aug 25. Oncol Res. 2018. PMID: 28877780 Free PMC article.
-
Antisense oligonucleotide treatment enhances the recovery of acute lung injury through IL-10-secreting M2-like macrophage-induced expansion of CD4+ regulatory T cells.J Immunol. 2013 Apr 15;190(8):4337-48. doi: 10.4049/jimmunol.1203233. Epub 2013 Mar 20. J Immunol. 2013. PMID: 23514739 Free PMC article.
-
miR-129-5p inhibits clear cell renal cell carcinoma cell proliferation, migration and invasion by targeting SPN.Cancer Cell Int. 2021 May 17;21(1):263. doi: 10.1186/s12935-021-01820-3. Cancer Cell Int. 2021. PMID: 34001147 Free PMC article.
-
Selective expression of tumor necrosis factor-related apoptosis-inducing ligand mediated by microRNA suppresses renal carcinoma growth.Mol Cell Biochem. 2014 Jul;392(1-2):125-34. doi: 10.1007/s11010-014-2025-3. Epub 2014 May 1. Mol Cell Biochem. 2014. PMID: 24788726
-
High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients.Br J Cancer. 2013 Sep 3;109(5):1123-9. doi: 10.1038/bjc.2013.443. Epub 2013 Aug 6. Br J Cancer. 2013. PMID: 23922109 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous